ArticleeLife2020
An adjunctive therapy administered with an antibiotic prevents enrichment of antibiotic-resistant clones of a colonizing opportunistic pathogen.
Article in eLife, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 27 citations in OpenAlex.
- An Engineered Solidified Peptide Hemocyte Sponge as Nanomotor Storage to Combat Bacterial Colitis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Polymeric Anti-Antibiotic Microparticles to Prevent Antibiotic Resistance Evolution.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Comprehensive analysis of antimicrobial resistance dynamics among broiler and duck intensive production systems.Scientific reports · 2025Article
- Drug repurposing of Nifuratel against methicillin-resistantFrontiers in cellular and infection microbiology · 2025Article
- Antibiotics and Lipid-Modifying Agents: Potential Drug-Drug Interactions and Their Clinical Implications.Pharmacy (Basel, Switzerland) · 2023Review
- The future of evolutionary medicine: sparking innovation in biomedicine and public health.Frontiers in science · 2023Article
- Nanomaterials for Delivering Antibiotics in the Therapy of Pneumonia.International journal of molecular sciences · 2022Review
- Antimicrobial Peptides Therapy: An Emerging Alternative for Treating Drug-Resistant Bacteria.The Yale journal of biology and medicine · 2022Review
- Antimicrobial drug resistance against Escherichia coli and its harmful effect on animal health.Veterinary medicine and science · 2022Review
- An orally administered drug prevents selection for antibiotic-resistant bacteria in the gut during daptomycin therapy.Evolution, medicine, and public health · 2022Article
- Evolutionary medicine.eLife · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
A key challenge in antibiotic stewardship is figuring out how to use antibiotics therapeutically without promoting the evolution of antibiotic resistance. Here, we demonstrate proof of concept for an adjunctive therapy that allows intravenous antibiotic treatment without driving the evolution and onward transmission of resistance. We repurposed the FDA-approved bile acid sequestrant cholestyramine, which we show binds the antibiotic daptomycin, as an 'anti-antibiotic' to disable systemically-administered daptomycin reaching the gut. We hypothesized that adjunctive cholestyramine could enable therapeutic daptomycin treatment in the bloodstream, while preventing transmissible resistance emergence in opportunistic pathogens colonizing the gastrointestinal tract. We tested this idea in a mouse model of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.